NPA Raises Issues of CBD and Counterfeit Products in Letter to Congress

Washington, D.C.—The National Products Association (NPA) has welcomed new Congress members with a letter expressing concern regarding the lack of action from the FDA on both cannabidiol (CBD) enforcement and counterfeit products entering the U.S., according to a press release.

The letter stated: “The Agency has had ample opportunities to issue their full authorities on products purported to contain CBD as well as counterfeit products entering the United States. Dietary supplement marketing, manufacturing, labeling, and advertising are all covered by regulations enforced by the FDA and the Federal Trade Commission (FTC). Under the provisions of DSHEA, the manufacturer of a dietary supplement or dietary ingredient is responsible for ensuring that the product is safe before marketing. Once a product has reached the U.S. market, FDA is responsible for monitoring and has the authority to remove any unsafe dietary supplement product. However, our industry has experienced several occasions where the FDA has failed to act.”

Related: NPA Says New AMA Policy Ignores Safety Record of Supplements
2020 Dietary Guidelines Released: Industry Reacts
Preparing for a Post-COVID World

The letter also requested support for legislation that would allow nutritional and dietary supplements to be reimbursable through FSAs and HSAs, and encouraged members of congress to join the Congressional Dietary Supplements Congress.

Daniel Fabricant, Ph.D., President and CEO of NPA, said in the press release: “We recognize the historical challenges policymakers are facing during the pandemic. However, the COVID-19 crisis should not preclude the FDA from executing its important responsibilities in other areas. We welcome the new Congress and look forward to getting to work on issues that are critical to the health and safety of millions of Americans.”